| Intrinsic brain activity triggers trigeminal meningeal afferents in a migraine model H Bolay, U Reuter, AK Dunn, Z Huang, DA Boas, MA Moskowitz Nature medicine 8 (2), 136-142, 2002 | 1588 | 2002 |
| A controlled trial of erenumab for episodic migraine PJ Goadsby, U Reuter, Y Hallström, G Broessner, JH Bonner, F Zhang, ... New England Journal of Medicine 377 (22), 2123-2132, 2017 | 910 | 2017 |
| Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial S Tepper, M Ashina, U Reuter, JL Brandes, D Doležil, S Silberstein, ... The Lancet Neurology 16 (6), 425-434, 2017 | 784 | 2017 |
| Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind … U Reuter, PJ Goadsby, M Lanteri-Minet, S Wen, P Hours-Zesiger, ... The Lancet 392 (10161), 2280-2287, 2018 | 455 | 2018 |
| Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial H Sun, DW Dodick, S Silberstein, PJ Goadsby, U Reuter, M Ashina, ... The Lancet Neurology 15 (4), 382-390, 2016 | 397 | 2016 |
| European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention S Sacco, L Bendtsen, M Ashina, U Reuter, G Terwindt, DD Mitsikostas, ... The journal of headache and pain 20, 1-33, 2019 | 389 | 2019 |
| Delayed inflammation in rat meninges: implications for migraine pathophysiology U Reuter, H Bolay, I Jansen-Olesen, A Chiarugi, MS del Rio, ... Brain 124 (12), 2490-2502, 2001 | 376 | 2001 |
| Diagnosis and management of migraine in ten steps AK Eigenbrodt, H Ashina, S Khan, HC Diener, DD Mitsikostas, AJ Sinclair, ... Nature Reviews Neurology 17 (8), 501-514, 2021 | 312 | 2021 |
| Products of hemolysis in the subarachnoid space inducing spreading ischemia in the cortex and focal necrosis in rats: a model for delayed ischemic neurological deficits after … JP Dreier, N Ebert, J Priller, D Megow, U Lindauer, R Klee, U Reuter, ... Journal of neurosurgery 93 (4), 658-666, 2000 | 307 | 2000 |
| Non-invasive vagus nerve stimulation for PREVention and Acute treatment of chronic cluster headache (PREVA): a randomised controlled study C Gaul, HC Diener, N Silver, D Magis, U Reuter, A Andersson, EJ Liebler, ... Cephalalgia 36 (6), 534-546, 2016 | 276 | 2016 |
| High‐dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre C Boehnke, U Reuter, U Flach, S Schuh‐Hofer, KM Einhäupl, G Arnold European Journal of Neurology 11 (7), 475-477, 2004 | 252 | 2004 |
| Nuclear factor‐κB as a molecular target for migraine therapy U Reuter, A Chiarugi, H Bolay, MA Moskowitz Annals of Neurology: Official Journal of the American Neurological …, 2002 | 238 | 2002 |
| BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study HC Diener, P Barbanti, C Dahlöf, U Reuter, J Habeck, J Podhorna Cephalalgia 31 (5), 573-584, 2011 | 234 | 2011 |
| Efficacy and tolerability of lasmiditan, an oral 5-HT1F receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, dose … M Färkkilä, HC Diener, G Géraud, M Láinez, J Schoenen, N Harner, ... The Lancet Neurology 11 (5), 405-413, 2012 | 212 | 2012 |
| Erenumab in chronic migraine with medication overuse: subgroup analysis of a randomized trial SJ Tepper, HC Diener, M Ashina, JL Brandes, DI Friedman, U Reuter, ... Neurology 92 (20), e2309-e2320, 2019 | 210 | 2019 |
| Headache and pregnancy: a systematic review A Negro, Z Delaruelle, TA Ivanova, S Khan, R Ornello, B Raffaelli, A Terrin, ... The journal of headache and pain 18, 1-20, 2017 | 210 | 2017 |
| Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan – A randomised proof-of-concept trial MD Ferrari, M Färkkilä, U Reuter, A Pilgrim, C Davis, M Krauss, HC Diener, ... Cephalalgia 30 (10), 1170-1178, 2010 | 198 | 2010 |
| European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention–2022 update S Sacco, FM Amin, M Ashina, L Bendtsen, CI Deligianni, R Gil-Gouveia, ... The journal of headache and pain 23 (1), 67, 2022 | 185 | 2022 |
| Animal models of migraine: looking at the component parts of a complex disorder A Bergerot, PR Holland, S Akerman, T Bartsch, AH Ahn, ... European Journal of Neuroscience 24 (6), 1517-1534, 2006 | 168 | 2006 |
| Cessation versus continuation of 6-month migraine preventive therapy with topiramate (PROMPT): a randomised, double-blind, placebo-controlled trial HC Diener, R Agosti, G Allais, P Bergmans, G Bussone, B Davies, M Ertas, ... The Lancet Neurology 6 (12), 1054-1062, 2007 | 163 | 2007 |
